Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed Press Release - "Wockhardt''s Zaynich (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary infection (cUTI) achieving 96.8% clinical cure rate"